You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Drug-related adverse events reported by ≥ 5% of subjects

From: Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

Event by body system ABC/EFV/ddI (N = 24) ABC/EFV/ddI/HU (N = 30)
  n (%) n (%)
Ear, nose, and throat   
   Nasal signs and symptoms 2 (8) 0
Endocrine and metabolic   
   Lack of appetite 1 (4) 3 (10)
   Lipid metabolism disorders 2 (8) 2 (7)
   Weight problems 0 2 (7)
Gastrointestinal   
   Abdominal distension 1 (4) 2 (7)
   Diarrhea 5 (21) 6 (20)
   Gaseous symptoms 0 2 (7)
   GI discomfort and pain 0 3 (10)
   Nausea 3 (13) 9 (30)
   Nausea and vomiting 1 (4) 6 (20)
Musculoskeletal   
   Arthralgia 1 (4) 2 (7)
Neurology   
   Abnormal dreams 5 (21) 4 (13)
   Cognitive function 2 (8) 1 (3)
   disorders 2 (8) 1 (3)
   Dizziness 1 (4) 4 (13)
   Headache 1 (4) 5 (17)
   Memory effects 0 2 (7)
   Neuropathy 1 (4) 4 (13)
   Sleep disorders 0 2 (7)
Non-site specific   
   ABC hypersensitivity 1 (4) 3 (10)
   Malaise and fatigue 2 (8) 6 (20)
Psychiatric   
   Depressive disorders 2 (8) 1 (3)
Skin   
   Nail disorders 0 2 (7)
   Skin rashes 3 (13) 3 (10)
  1. Note: ABC, abacavir; ddI, didanosine; EFV, efavirenz; HU, hydroxyurea